BMS revises hepatitis B therapy warning label

Share this article:
The FDA reports that Bristol-Myers Squibb has revised hepatitis B therapy Baraclude's boxed warning labeling to caution against its use in HIV/hepatitis B virus co-infected patients who are not also receiving highly active antiretroviral therapy due to the potential for developing HIV resistance.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions